STOCK TITAN

Integrated BioPharma (INBP) 10-K Filings

INBP OTC

Here are the 10-K annual reports from Integrated BioPharma Inc (INBP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow INBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INBP filings page.

Rhea-AI Summary

Integrated BioPharma, Inc. reported fiscal 2026 net sales of $43.872 million, down 19.3% from $54.353 million in fiscal 2025. Gross profit was $0.800 million, compared with $5.562 million. The company recorded an operating loss of $2.705 million versus operating income of $2.020 million, and a net loss of $2.842 million versus net income of $0.808 million.

Net cash provided by operating activities was $1.241 million, compared with $2.065 million; year-end cash rose to $4.471 million from $3.615 million. Two customers, Life Extension and Herbalife, accounted for approximately 90% of consolidated net sales in fiscal 2026, compared with 84% in fiscal 2025.

The committed revolving line of credit has a $4.000 million limit through April 14, 2027; a separate convertible line of credit note is capped at $250,000 for equipment and/or vehicle purchases. Management said operations, credit facilities and equipment financing are expected to support working capital requirements through the twelve-month period ending in September 2027. Agreements to develop, manufacture and supply products to Herbalife subsidiaries began January 1, 2026 and terminate December 31, 2028, without minimum purchase or supply commitments.

Rhea-AI Summary

Integrated BioPharma, Inc. (INBP) reports consolidated fiscal-year information and disclosures for the year ended June 30, 2025. The company states it has a cybersecurity program based on recognized standards and is not aware of any cybersecurity incidents that have materially affected its business. The balance sheet notes 50,000,000 shares authorized and roughly 31.1 million shares outstanding reported in the filing. The company recorded a $20 allowance for credit losses at June 30, 2025 (versus $1 at June 30, 2024). Two customers accounted for approximately 84% of consolidated net sales in 2025 and represented about 76% of accounts receivable at June 30, 2025. The filing discloses federal and state NOLs with limited realizability and a valuation allowance changes: a $830 reserve recorded against federal NOL-related deferred tax assets and a $347 release of the state NOL valuation reserve due to tax law change. Lease amendments and stock option plan details (plans with 4,659,652 shares remaining; recent option grants and exercise prices) are included, and a finance lease obligation of $485 due to a related party is disclosed.